Seattle Genetics Inc. (SGEN) ended a midstage trial, saying its
cancer drug dacetuzumab didn't look likely to meet the main goal of
the test.
The biotechnology company is collaborating on the drug's
development with Genentech Inc. (DNA), which Roche Holding AG
(RHHBY) bought earlier this year.
The company said a combination of drugs including dacetuzumab
failed to show an adequate response rate versus the combination of
drugs with a placebo. The drug, used in chemotherapy, was being
tested in patients with a type of lymphoma, a cancer that starts in
the lymph node immune system.
Seattle Genetics didn't specify exactly the primary endpoint
except to say the study was unlikely to reach it. A spokesman
wasn't immediately available for comment.
Chief Executive Clay Siegall said Seattle Genetics was
disappointed by having to end the study but said the drug is being
tested in patients with other types of cancer.
Results from an early-stage clinical trial evaluating
dacetuzumab combined with Rituxan and Gemzar will be announced Dec.
7. In the cancelled trial, dacetuzumab and placebo combined with
combination with Rituxan plus ifosfamide, carboplatin and etoposide
chemotherapy.
Seattle Genetics shares closed Friday at $13.16 and weren't
active premarket. The stock has more than doubled so far this
year.
-By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;
joan.solsman@dowjones.com
Order free Annual Report for Roche Holding Ltd
Visit http://djnewswires.ar.wilink.com/?link=RHHBY or call
1-888-301-0513